What is Protalix's gross profit margin?

What does Protalix do and what are its main business segments?

What is the market's earnings forecast for Protalix next quarter?

What guidance did Protalix's management provide for the next earnings period?

Did Protalix beat or miss consensus estimates last quarter?

What is Protalix's latest dividend and current dividend yield?

What were the key takeaways from Protalix’s earnings call?

What is the revenue and EPS growth rate for Protalix year over year?

- **Revenue Growth**: Year-to-date 2025 revenue up 24% to $43.6 million, despite Q3 2025 dip (-1% YoY).
- **Pipeline Momentum**: PRX-115 Phase II trial set to begin in Q4 2025; CHMP reexamination decision expected Q1 2026.
- **Financial Strength**: $29.4 million cash balance, 12-month runway, and 33% YoY net income growth.
- **Strategic Focus**: Balancing R&D investment (58% YoY R&D spend increase) with disciplined commercial execution.

**【CEO Summary Section】**
- **Revenue Performance**: Year-to-date 2025 total revenues reached $43.6 million (+24% YoY), driven by Elfabrio sales to Chiesi, Pfizer, and Fiocruz. Q3 2025 revenue was $17.9 million (-1% YoY) due to partner inventory management variability.
- **Pipeline Progress**: PRX-115 Phase II trial for uncontrolled gout is set to begin in Q4 2025, following FDA IND approval. The company believes PRX-115 could be a best-in-class uricase therapy with a long-acting profile.
- **Regulatory Update**: Chiesi requested reexamination of the CHMP's negative opinion on Elfabrio's 4-week dosing regimen; a decision is expected in Q1 2026. The currently approved 2-week regimen remains unaffected.
- **Financial Position**: Strong cash balance of $29.4 million as of Q3 2025, supporting R&D investments (e.g., PRX-115 Phase II) and commercial operations.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Q3 2025 sales to Chiesi ($8.8M), Pfizer ($2.8M), and Fiocruz ($6.1M). Year-to-date R&D expenses rose 58% to $13.9 million, driven by PRX-115 preparations.
- **Profitability**: Q3 2025 net income of $2.4 million (+33% YoY), with a 12-month cash runway.
- **Cost Management**: SG&A decreased 11% YoY to $8.2 million, reflecting reduced selling expenses.

**【Q&A Key Highlights】**
- **CHMP Timeline**: Reexamination decision expected Q1 2026; no new trials planned unless needed post-reexamination.
- **PRX-115 Trial**: Phase II initiation in Q4 2025, with top-line results anticipated in Q3 2027.
- **Revenue Visibility**: Gilad Mamlok emphasized predictable royalty streams from Elfabrio, though quarterly fluctuations may occur due to partner inventory timing.
- **Pipeline Expansion**: PRX-119 in early development, with updates pending preclinical results.
- **Global Expansion**: Chiesi pursuing new Elfabrio approvals in additional markets, though no new approvals disclosed since last update.

Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript

Selling Products

Revenues From License And Research And Development Services

PLX

PLX fundamentals

You can ask Aime